Skip to content
DataLookout
Menu

AbbVie clinical trial pipeline

Get alerts when AbbVie's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-22

What changed in the last 30 days

31 trials changed in the last 30 days: 0 stopped, 6 with notable changes, 25 with minor changes only.

  1. Minor: Upadacitinib · Alopecia Areata Trial sites expanded: 13 → 22 locations AbbViePhase 3 NCT07772492
  2. Minor: NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness Trial sites expanded: 4 → 7 locations AbbViePhase 3 NCT07880756
  3. Minor: Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment · Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trial sites expanded: 3 → 9 locations AbbViePhase 2 NCT07744126
  4. Minor: Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 · Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) Trial sites expanded: 13 → 17 locations AbbViePhase 1 NCT07607964
  5. Minor: IMGN632 · Untreated BPDCN and Relapsed/Refractory BPDCN Trial completed AbbViePhase 1/2 NCT03386513
  6. Minor: REVIVAL · Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine · Acute Myeloid Leukemia (AML) Trial sites expanded: 36 → 40 locations AbbViePhase 2/3 NCT07581002
  7. Minor: AndroMETa-CRC · Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil · Refractory Metastatic Colorectal Cancer Trial sites expanded: 87 → 91 locations AbbViePhase 3 NCT07525206
  8. Minor: Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA · Moderate to Severe Upper Facial Lines Trial sites expanded: 21 → 24 locations AbbViePhase 2 NCT07871513
  9. Minor: Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor · Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations Trial sites expanded: 127 → 131 locations AbbViePhase 1/2 NCT06772623
  10. Minor: 3112 Ped BPD · Change in Disease Activity and Adverse Events (AEs) With Cariprazine · Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder Enrollment reduced: 380 → 338 participants AbbViePhase 3 NCT04777357
  11. Notable: Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies · Relapsed or Refractory Multiple Myeloma Recruitment opened AbbViePhase 3 NCT07728188
  12. Minor: H25-878 ORCHES · Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's Disease Trial completed AbbVieNot specified NCT06937034
  13. Minor: AAVIATE · RGX-314 Gene Therapy Administered in the Suprachoroidal Space · Neovascular Age-Related Macular Degeneration (nAMD) Primary completion date changed from estimate of Aug 2026 to Oct 13, 2026 AbbViePhase 2 NCT04514653
  14. Minor: ALTITUDE® · RGX-314 Gene Therapy Administered in the Suprachoroidal Space · Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) Trial completed AbbViePhase 2 NCT04567550
  15. Minor: How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants Trial completed AbbViePhase 1 NCT07680686
  16. Minor: Step-Up HS · Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent · Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy Primary completion pushed from Mar 2028 to Aug 2028 AbbViePhase 3 NCT05889182
  17. Minor: Change in Disease Activity and Adverse Events in Adolescent and Adult · Moderate to Severe Active Crohn's Disease (CD) in Japan Trial completed AbbVieNot specified NCT06023030
  18. Notable: Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) · Relapsed or Refractory Multiple Myeloma Primary endpoint(s) modified AbbViePhase 1 NCT05650632
  19. Notable: PUCCINI · Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease Primary endpoint(s) modified AbbVieNot specified NCT07227896
  20. Notable: Targeted Therapies · Active Psoriatic Arthritis Primary and study completion dates pushed to Aug 2029 AbbViePhase 2 NCT06865105
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-13 NCT07935564 A Study to Assess the Adverse Events and How Oral ABBV-1606 Moves Through the Body of… Phase 1 Not Yet Recruiting
2026-11-12 NCT07933211 A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of… Phase 2/3 Not Yet Recruiting
2026-11-12 NCT07933497 M4 Receptor PET Radioligand Validation Study in Healthy Adults Early Phase 1 Not Yet Recruiting
2026-11-12 NCT07933536 A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe… Phase 2 Not Yet Recruiting
2026-11-09 NCT07925983 A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move… Phase 1 Recruiting
2026-10-29 NCT07904754 Platform Study of Targeted Therapies for Adults With Moderately to Severely Active… Phase 2 Not Yet Recruiting
2026-10-27 NCT07896421 Real-World Study of Mirvetuximab Soravtansine in Adult Participants With… Recruiting
2026-10-27 NCT07896434 A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young… Phase 3 Not Yet Recruiting
2026-10-26 NCT07895043 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… Phase 2 Not Yet Recruiting
2026-10-26 NCT07895056 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… Phase 2 Not Yet Recruiting

Active trials by phase

Early Phase 1
1
Phase 1
51
Phase 1/2
9
Phase 2
52
Phase 2/3
11
Phase 3
63
Phase 4
4
Not charted: 48 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 52

Get alerts when AbbVie's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free